GSK plc (LON:GSK)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 83.22B +42.7% |
| Revenue (ttm) | 32.67B +4.1% |
| Net Income | 5.72B +122.0% |
| EPS | 1.39 +123.2% |
| Shares Out | 4.01B |
| PE Ratio | 14.96 |
| Forward PE | 11.57 |
| Dividend | 0.72 (3.40%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 8,767,085 |
| Average Volume | 11,128,379 |
| Open | 2,114.00 |
| Previous Close | 2,115.00 |
| Day's Range | 2,071.03 - 2,135.00 |
| 52-Week Range | 1,242.50 - 2,282.00 |
| Beta | 0.32 |
| RSI | 45.84 |
| Earnings Date | Feb 4, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial StatementsNews
Emma Walmsley’s pay rose almost 50% to £15.6m in final year as GSK boss
Bulk of 2025 renumeration came from share bonuses as drug company’s now former CEO benefitted from stock rise Business live – latest updates GSK awarded Emma Walmsley a near-50% pay rise to £15.6m in ...
SCYNEXIS Posts Narrower FY25 Loss, Advances Next-Gen Antifungal Pipeline
(RTTNews) - SCYNEXIS, Inc. (SCYX) has reported its full-year 2025 results, while highlighting progress across its antifungal pipeline, including its next-generation candidate SCY-247 and updates on it...
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Ph...
Price Over Earnings Overview: GSK
Looking into the current session, GSK Inc. (NYSE: GSK) shares are trading at $57.03, after a 0.76% drop. Over the past month, the stock fell by 1.03% , but over the past year, it actually spiked by 4...
GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Off Plan
GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Off Plan
GSK PLC (GSK) Shares Gap Down to $56.525 on Mar 3
GSK PLC (GSK) Shares Gap Down to $56.525 on Mar 3
GSK Completes Acquisition of Rapt Therapeutics for $2.2B
GSK Completes Acquisition of Rapt Therapeutics for $2.2B
FENI, GSK, BTI, RIO: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Fidelity Enhanced International ETF (Symbol: FENI) where we have detec...
ViiV Healthcare's (GSK) VH184 Shows Promising Phase 1 Results
ViiV Healthcare's (GSK) VH184 Shows Promising Phase 1 Results
GSK's ViiV Healthcare Unveils Promising HIV Treatment Data
GSK's ViiV Healthcare Unveils Promising HIV Treatment Data
GSK's ViiV Healthcare Reports Promising Results from HIV Study
GSK's ViiV Healthcare Reports Promising Results from HIV Study
GSK secures Canadian made high blood pressure drug in US$950 million deal
CEO Luke Miels is under pressure to build up GSK’s portfolio before their patent of the HIV drug dolutegravir expires
GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play
GSK will acquire 35Pharma for $950 million, adding HS235, a new drug candidate targeting pulmonary hypertension affecting millions worldwide. ... Full story available on Benzinga.com
GSK to Buy 35Pharma for $950 Million
GSK struck a deal to buy Canada's 35Pharma as the U.K. drugmaker seeks to bolster its exposure to diseases linked to obesity.
GSK (GSK) Acquires 35Pharma for $950 Million to Expand RI&I Portfolio
GSK (GSK) Acquires 35Pharma for $950 Million to Expand RI&I Portfolio
GSK To Acquire 35Pharma For $950 Mln
(RTTNews) - GSK plc (GSK, GSK.L, GS71.DE) has entered an agreement to acquire 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of protein-base...
GSK to buy 35Pharma for $950 million
GSK on Wednesday agreed to buy Canadian biopharmaceutical company 35Pharma Inc for $950 million in cash.
GSK to acquire Canada's 35Pharma for $950M in cash
35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)
MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics today announc...
GSK Enters $1B Licensing Deal with Frontier Biotechnologies for siRNA Therapies
GSK Enters $1B Licensing Deal with Frontier Biotechnologies for siRNA Therapies
GSK inks licensing deal worth up to $1B with China’s Frontier Bio
GSK (GSK) stock is in focus as the company inks a drug licensing deal worth up to $1B with China's Frontier Biotechnologies for siRNA treatments. Read more here.
Frontier Biotechnologies strikes up to $1 billion deal with GSK
Frontier Biotechnologies said on Tuesday it has struck a deal with GSK , granting the British drugmaker worldwide rights to develop two small interfering RNA therapies targeting kidney diseases in an ...
Bora Pharmaceuticals Signs $250 Mln Five-Year Manufacturing Deal With GSK; Bora Stock Up
(RTTNews) - Bora Pharmaceuticals Co., Ltd. (6472.TW, BORAY), a Taiwan-based international pharmaceutical company, on Monday announced a renewed five-year manufacturing partnership with a pharmaceutica...
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract.